287 related articles for article (PubMed ID: 27102921)
21. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
[TBL] [Abstract][Full Text] [Related]
23. Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis.
Berthold E; Månsson B; Gullstrand B; Geborek P; Saxne T; Bengtsson AA; Kahn R
Scand J Rheumatol; 2018 Jan; 47(1):22-26. PubMed ID: 28485187
[TBL] [Abstract][Full Text] [Related]
24. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
[TBL] [Abstract][Full Text] [Related]
25. Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.
Sfriso P; Caso F; Filardo GS; Botsios C; Costa L; Scarpa R; Todesco S; Spinella P; Oliviero F; Punzi L
Clin Rheumatol; 2016 Jun; 35(6):1615-8. PubMed ID: 27048267
[TBL] [Abstract][Full Text] [Related]
26. Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels.
Jones JD; Hamilton BJ; Challener GJ; de Brum-Fernandes AJ; Cossette P; Liang P; Masetto A; Ménard HA; Carrier N; Boyle DL; Rosengren S; Boire G; Rigby WF
Arthritis Res Ther; 2014 Apr; 16(2):R103. PubMed ID: 24766912
[TBL] [Abstract][Full Text] [Related]
27. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
28. Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis.
Ichikawa T; Kageyama Y; Kobayashi H; Kato N; Tsujimura K; Koide Y
Rheumatol Int; 2010 Apr; 30(6):725-30. PubMed ID: 20062995
[TBL] [Abstract][Full Text] [Related]
29. Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis.
Blaschke S; Rinke K; Maring M; Flad T; Patschan S; Jahn O; Mueller CA; Mueller GA; Dihazi H
Arthritis Res Ther; 2015 Mar; 17(1):45. PubMed ID: 25884688
[TBL] [Abstract][Full Text] [Related]
30. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
[TBL] [Abstract][Full Text] [Related]
31. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
[TBL] [Abstract][Full Text] [Related]
32. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.
Wampler Muskardin T; Vashisht P; Dorschner JM; Jensen MA; Chrabot BS; Kern M; Curtis JR; Danila MI; Cofield SS; Shadick N; Nigrovic PA; St Clair EW; Bingham CO; Furie R; Robinson W; Genovese M; Striebich CC; O'Dell JR; Thiele GM; Moreland LW; Levesque M; Bridges SL; Gregersen PK; Niewold TB
Ann Rheum Dis; 2016 Oct; 75(10):1757-62. PubMed ID: 26546586
[TBL] [Abstract][Full Text] [Related]
33. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis.
Rosengren S; Wei N; Kalunian KC; Kavanaugh A; Boyle DL
Rheumatology (Oxford); 2011 Mar; 50(3):603-10. PubMed ID: 21098574
[TBL] [Abstract][Full Text] [Related]
34. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
35. B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.
Moura RA; Quaresma C; Vieira AR; Gonçalves MJ; Polido-Pereira J; Romão VC; Martins N; Canhão H; Fonseca JE
PLoS One; 2017; 12(9):e0182927. PubMed ID: 28886017
[TBL] [Abstract][Full Text] [Related]
36. CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients.
Wang C; Wu K; Yu Q; Zhang S; Gao Z; Liu Y; Ni L; Cheng Y; Guan Z; Shi M; Lu H; Lou Y; Zhou P
Sci Rep; 2016 Sep; 6():33569. PubMed ID: 27650493
[TBL] [Abstract][Full Text] [Related]
37. CXCL 9 and CXCL 10 as Sensitive markers of disease activity in patients with rheumatoid arthritis.
Kuan WP; Tam LS; Wong CK; Ko FW; Li T; Zhu T; Li EK
J Rheumatol; 2010 Feb; 37(2):257-64. PubMed ID: 20032101
[TBL] [Abstract][Full Text] [Related]
38. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis.
Eriksson C; Rantapää-Dahlqvist S; Sundqvist KG
Scand J Rheumatol; 2013; 42(4):260-5. PubMed ID: 23379516
[TBL] [Abstract][Full Text] [Related]
39. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis.
Iagnocco A; Finucci A; Ceccarelli F; Perricone C; Iorgoveanu V; Valesini G
Rheumatology (Oxford); 2015 Oct; 54(10):1890-6. PubMed ID: 26070937
[TBL] [Abstract][Full Text] [Related]
40. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
